Literature DB >> 10650786

Clinicopathological significance of the expression of CD44v2 in colorectal cancer.

K Haruyama1, Y Matsumura, Y Moriya, T Kakizoe, A Ochiai, M Kawaguchi, T Saito.   

Abstract

Expression of CD44 variant isoforms has been reported to be correlated with faster progression of neoplastic diseases, metastasis and reduced survival period. In this study, the correlation between the expression of CD44v2 (v2) or CD44v6 (v6) and clinicopathological features was examined in Dukes B and C colorectal cancer using immunohistochemistry. V6 expression was not correlated with any clinicopathological indices or prognosis in either Dukes B or C. On the other hand, v2 expression was correlated significantly with recurrence rate and poorer prognosis in Dukes B colorectal cancer although there was no correlation between v2 expression and prognosis in Dukes C patients. The results suggest that v2 is a candidate for a prognostic marker in Dukes B colorectal cancer. CD44v2 expression may be an indication for adopting adjuvant chemotherapy in patients without lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10650786

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Self-assembling HA/PEI/dsRNA-p21 ternary complexes for CD44 mediated small active RNA delivery to colorectal cancer.

Authors:  Chen-Lin Feng; Yan-Xing Han; Hui-Hui Guo; Xiao-Lei Ma; Zhi-Qiang Wang; Lu-Lu Wang; Wen-Sheng Zheng; Jian-Dong Jiang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

2.  Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression.

Authors:  Balázs Bánky; Lívia Rásó-Barnett; Tamás Barbai; József Tímár; Péter Becságh; Erzsébet Rásó
Journal:  Mol Cancer       Date:  2012-11-14       Impact factor: 27.401

3.  Demonstration of a melanoma-specific CD44 alternative splicing pattern that remains qualitatively stable, but shows quantitative changes during tumour progression.

Authors:  Livia Raso-Barnett; Balazs Banky; Tamas Barbai; Peter Becsagh; Jozsef Timar; Erzsebet Raso
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.